Literature DB >> 15674023

Kinetic exclusion assay technology: characterization of molecular interactions.

Ryan J Darling1, Pierre-Alexandre Brault.   

Abstract

Characterization of intermolecular interactions in terms of affinity, binding kinetics, stoichiometry, specificity, and thermodynamics can facilitate the selection of lead compounds in the discovery and development of protein therapeutics. KinExA (Sapidyne Instruments, Inc., Boise, ID) is a relatively new technology that is gaining use in characterizing molecular interactions, particularly with respect to antibody therapeutics. KinExA offers a platform that allows the measurement of true equilibrium binding affinity and kinetics using unmodified molecules in solution phase. This is accomplished by using a solid-phase immobilized molecule to probe for free concentration of one interaction component after allowing sufficient time to reach equilibrium (affinity measurements), or under pre-equilibrium conditions (kinetics). In this review, the theory behind KinExA technology is discussed, and examples of applying this technology to antibody characterization are provided. Finally, a comparison among KinExA, Biacore (surface plasmon resonance), and isothermal titration calorimetry is presented, and potential future improvements and applications of KinExA are discussed.

Mesh:

Substances:

Year:  2004        PMID: 15674023     DOI: 10.1089/adt.2004.2.647

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  24 in total

1.  Quantitation of protein-protein interactions by thermal stability shift analysis.

Authors:  Curtis J Layton; Homme W Hellinga
Journal:  Protein Sci       Date:  2011-07-11       Impact factor: 6.725

2.  Cell-Binding Assays for Determining the Affinity of Protein-Protein Interactions: Technologies and Considerations.

Authors:  S A Hunter; J R Cochran
Journal:  Methods Enzymol       Date:  2016-08-08       Impact factor: 1.600

3.  Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration.

Authors:  Yanting Duan; Bo Hu; Chunxia Qiao; Longlong Luo; Xinying Li; Jing Wang; Hao Liu; Tingting Zhou; Beifen Shen; Ming Lv; Jiannan Feng
Journal:  Oncol Lett       Date:  2019-04-15       Impact factor: 2.967

4.  Nucleoporin Nup50 stabilizes closed conformation of armadillo repeat 10 in importin α5.

Authors:  Ruth A Pumroy; Jonathan D Nardozzi; Darren J Hart; Michael J Root; Gino Cingolani
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

5.  Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity.

Authors:  Maria A T Groves; Lily Amanuel; Jamie I Campbell; D Gareth Rees; Sudharsan Sridharan; Donna K Finch; David C Lowe; Tristan J Vaughan
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

6.  A novel approach for measuring sphingosine-1-phosphate and lysophosphatidic acid binding to carrier proteins using monoclonal antibodies and the Kinetic Exclusion Assay.

Authors:  Jonathan K Fleming; Thomas R Glass; Steve J Lackie; Jonathan M Wojciak
Journal:  J Lipid Res       Date:  2016-07-21       Impact factor: 5.922

7.  Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors.

Authors:  Yasmina Noubia Abdiche; Dan Stephen Malashock; Jaume Pons
Journal:  Protein Sci       Date:  2008-05-27       Impact factor: 6.725

8.  An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.

Authors:  Mihalis S Kariolis; Yu Rebecca Miao; Douglas S Jones; Shiven Kapur; Irimpan I Mathews; Amato J Giaccia; Jennifer R Cochran
Journal:  Nat Chem Biol       Date:  2014-09-21       Impact factor: 15.040

9.  Computational modeling of microfluidic data provides high-throughput affinity estimates for monoclonal antibodies.

Authors:  Sonia Budroni; Francesca Buricchi; Andrea Cavallone; Gianfranco Volpini; Alessandra Mariani; Paola Lo Surdo; Christoph J Blohmke; Giuseppe Del Giudice; Duccio Medini; Oretta Finco
Journal:  Comput Struct Biotechnol J       Date:  2021-06-17       Impact factor: 7.271

10.  A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.

Authors:  Shuji Sato; Andrew W Drake; Isamu Tsuji; Jinhong Fan
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.